The acquisition, pathologic analysis and molecular characterization of human and mouse model gastrointestinal (GI) samples is an integral requirement for all portions of this SPORE. This Core will continue to provide SPORE investigators multiple pathology services to support Research Projects and future Career Enhancement Program (CEP) and Developmental Projects (DP) awardees. We will work in close collaboration with investigators to achieve three crucial purposes: i) to provide tissue specimens and pathology expertise to evaluate human and mouse models of GI neoplasms; ii) to provide molecular pathologic expertise in state-of-the-art molecular evaluation of tissue specimens; and iii) to evaluate and implement new tissue and cellular imaging and analysis technologies that will benefit these research goals in the future. Centralization of Core activities builds upon established infrastructure and expertise of these investigators, and complements but does not replicate existing infrastructure in our Cancer Center and provides a valuable component to the analysis of biological resources developed and utilized by SPORE investigators. To bring pathology based scientific support to all SPORE projects, this Core proposes the following specific aims:
Specific Aim 1 : To provide human biospecimen procurement and distribution.
Specific Aim 2 : Generation of models for pre-clinical trials Specific Aim 3: Pathologic characterization of human and mouse GI tumors using molecular pathology tools and emerging new technologies
The Biospecimen and Pathology Core will work in close collaboration with investigators to achieve three crucial purposes: i) to provide tissue specimens and pathology expertise to evaluate human and mouse models of GI neoplasms; ii) to provide molecular pathologic expertise in state-of-the-art molecular evaluation of tissue specimens; and iii) to evaluate and implement new tissue and cellular imaging and analysis technologies that will benefit these research goals in the future.
| Danai, Laura V; Babic, Ana; Rosenthal, Michael H et al. (2018) Altered exocrine function can drive adipose wasting in early pancreatic cancer. Nature 558:600-604 |
| Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K et al. (2018) Genetic Mechanisms of Immune Evasion in Colorectal Cancer. Cancer Discov 8:730-749 |
| Corcoran, Ryan B; André, Thierry; Atreya, Chloe E et al. (2018) Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal Cancer. Cancer Discov 8:428-443 |
| Song, Mingyang; Wu, Kana; Meyerhardt, Jeffrey A et al. (2018) Fiber Intake and Survival After Colorectal Cancer Diagnosis. JAMA Oncol 4:71-79 |
| Babic, A; Schnure, N; Neupane, N P et al. (2018) Plasma inflammatory cytokines and survival of pancreatic cancer patients. Clin Transl Gastroenterol 9:145 |
| Lopes-Ramos, Camila M; Kuijjer, Marieke L; Ogino, Shuji et al. (2018) Gene Regulatory Network Analysis Identifies Sex-Linked Differences in Colon Cancer Drug Metabolism. Cancer Res 78:5538-5547 |
| Van Blarigan, Erin L; Ou, Fang-Shu; Niedzwiecki, Donna et al. (2018) Dietary Fat Intake after Colon Cancer Diagnosis in Relation to Cancer Recurrence and Survival: CALGB 89803 (Alliance). Cancer Epidemiol Biomarkers Prev 27:1227-1230 |
| Patra, Krushna C; Kato, Yasutaka; Mizukami, Yusuke et al. (2018) Mutant GNAS drives pancreatic tumourigenesis by inducing PKA-mediated SIK suppression and reprogramming lipid metabolism. Nat Cell Biol 20:811-822 |
| Katona, Bryson W; Yurgelun, Matthew B; Garber, Judy E et al. (2018) A counseling framework for moderate-penetrance colorectal cancer susceptibility genes. Genet Med 20:1324-1327 |
| Jeon, Jihyoun; Du, Mengmeng; Schoen, Robert E et al. (2018) Determining Risk of Colorectal Cancer and Starting Age of Screening Based on Lifestyle, Environmental, and Genetic Factors. Gastroenterology 154:2152-2164.e19 |
Showing the most recent 10 out of 590 publications
